abstract |
The present invention provides compositions and methods featuring the use of miR-629 to identify patients responsive to B cell depletion therapies (e. G., Treatment with an anti-CD19 antibody). In another embodiment, the invention features the use of miR-629 to identify a subject with B cell malignancy. |